Valneva SE
Specialty vaccine company developing and commercializing vaccines for infectious diseases.
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-03-08 07:00 |
Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya…
|
English | 245.9 KB | ||
| 2022-03-04 08:30 |
VALNEVA Déclaration d’actions et de droits de vote - 28 février 2022
|
French | 356.3 KB | ||
| 2022-03-04 08:30 |
VALNEVA Declaration of shares and voting rights - February 28, 2022
|
English | 18.7 KB | ||
| 2022-03-01 07:00 |
Bahrein autorise l’utilisation d’urgence du vaccin inactivé de Valneva contre l…
|
French | 399.0 KB | ||
| 2022-03-01 07:00 |
Valneva Receives Emergency Use Authorization from Bahrain for its Inactivated C…
|
English | 313.0 KB | ||
| 2022-02-25 07:00 |
Valneva reçoit une évaluation initiale du CHMP pour son candidat vaccin inactiv…
|
French | 385.1 KB | ||
| 2022-02-25 07:00 |
Valneva Receives Initial CHMP Assessment of its Inactivated, Adjuvanted COVID-1…
|
English | 313.3 KB | ||
| 2022-02-21 07:00 |
Valneva se voit accorder un financement jusqu’à £20 millions par Scottish Enter…
|
French | 401.1 KB | ||
| 2022-02-21 07:00 |
Valneva Awarded Up to £20 Million by Scottish Enterprise to Advance Vaccine Dev…
|
English | 317.5 KB | ||
| 2022-02-04 19:30 |
Déclaration d’actions et de droits de vote de la société Valneva SE - Janvier 2…
|
French | 358.2 KB | ||
| 2022-02-04 19:30 |
VALNEVA SE Declaration of shares and voting rights - January 2022
|
English | 103.6 KB | ||
| 2022-02-04 07:00 |
Valneva et Pfizer annoncent de nouvelles données positives de Phase 2 pour leur…
|
French | 490.8 KB | ||
| 2022-02-04 07:00 |
Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccin…
|
English | 592.9 KB | ||
| 2022-02-03 07:00 |
Valneva Reports Full Year 2021 Revenue and Cash; Provides First 2022 Guidance
|
English | 642.4 KB | ||
| 2022-02-03 07:00 |
Valneva publie son chiffre d’affaires et sa trésorerie pour l’exercice 2021 et …
|
French | 474.9 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valneva SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
Peer Companies
